DGAT2 and fatty liver disease: Conversely, DGAT2 alone cannot maintain the size and TAG content of secreted VLDLs (this study), although, as expected from its role in esterifying de novo synthesized FAs, previous studies have shown that it is fully capable of supporting hepatic steatosis (cytosolic LD-TAG synthesis) induced by an LXRα agonist, i.e., through endogenous hepatic lipogenesis (35).